Who is sponsoring NCT03477786?

NCT03477786 is sponsored by National Health Research Institutes, Taiwan.

What drugs are being tested in NCT03477786?

Interventions in NCT03477786: drug adjustment and behavioral modification.

What condition does NCT03477786 study?

NCT03477786 studies Type 2 Diabetes Mellitus, Hypertension.

Is NCT03477786 still recruiting?

NCT03477786 is currently status unknown. Last updated 26 March 2018.

Last reviewed 2018-03-26 · How we verify

NCT03477786: BM4DM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Blood Pressure Control for Type 2 Diabetes

Status unknown NA Last updated 26 March 2018

What this trial tests

NA trial testing drug adjustment and behavioral modification in Type 2 Diabetes Mellitus in 1,500 participants. Status unknown.

Timeline

28 October 2013

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	National Health Research Institutes, Taiwan
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	1,500
Start date	28 October 2013
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	2 locations across Taiwan

Drugs / interventions tested

drug adjustment and behavioral modification

Conditions studied

Type 2 Diabetes Mellitus — all drugs for Type 2 Diabetes Mellitus →
Hypertension — all drugs for Hypertension →

Sponsor

National Health Research Institutes, Taiwan

Who can join

Adults 30 to 75, any sex, with Type 2 Diabetes Mellitus or Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The BP4DM study was initiated as a prospective randomized controlled trial to investigate the renal protection effect for tight blood pressure control for Taiwanese T2DM patients without previously diagnosed CV events. We set our primary outcome for the prevention of microalbuminuria development. The secondary outcomes include mortality, annual renal function declining rate, and development of cardiovascular events. The recruitment period for the RCT trial is from 2013 Oct to 2019 Dec. In addition, we also intend to continuously follow up all our recruited hypertensive diabetes patients for at least 10 years to observe their clinical outcomes including cardiovascular, renal, retinal outcomes and mortality.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Validity of a Short Food Frequency Questionnaire Assessing Macronutrient and Fiber Intakes in Patients of Han Chinese Descent with Type 2 Diabetes.
Huang MC, Lin KD, Chen HJ, Wu YJ, et al · · 2018 · cited 20× · PMID 29857595 · DOI 10.3390/ijerph15061142
Inter-Relations between Dietary Patterns and Glycemic Control-Related Biomarkers on Risk of Retinopathy in Type 2 Diabetes.
Wu YJ, Hsu CC, Hwang SJ, Lin KD, et al · · 2024 · cited 2× · PMID 39064717 · DOI 10.3390/nu16142274

Verify or expand the search:

Other recruiting trials for Type 2 Diabetes Mellitus

Currently open trials in the same condition.

NCT07351058 — A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes · Phase 3 · recruiting
NCT07373938 — Carotid Wall Texture as a Cardiovascular Risk Biomarker in Type 2 Diabetes Mellitus · recruiting
NCT07433062 — A Study to Evaluate the Effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants With · Phase 1 · recruiting
NCT07276776 — An Evaluation of the Omnipod® M System in Adults With Type 2 Diabetes · NA · active not recruiting
NCT07232537 — An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic · recruiting

Other National Health Research Institutes, Taiwan trials

Trials by the same sponsor.

NCT07579832 — Quantitative Monitoring of Disability Care Quality for Long-Term Care Facilities 2 · NA · not yet recruiting
NCT06981637 — Pegylated Liposomal Doxorubicin (PLD) Versus Active Surveillance for Advanced Soft Tissue Sarcoma Patients Who Had Contr · Phase 2 · recruiting
NCT07177365 — Internet-Based Cognitive Behavioral Therapy With Treatment as Usual for Generalized Anxiety Disorder and Major Depressiv · NA · not yet recruiting
NCT07138261 — Taiwanese Anaplastic Thyroid Cancer Registry · not yet recruiting
NCT07151365 — Plant-based Diets and Healthy Aging · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03477786 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by National Health Research Institutes, Taiwan
Last refreshed: 26 March 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03477786.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing